Group 1 - The company, Jincheng Pharmaceutical, has submitted a patent application for the preparation method and application of nicotine salt compounds through its subsidiary [1] - The patent application is currently under review [1]

Group 1 - The company Jin Cheng Pharmaceutical reported that as of September 20, 2025, the total number of shareholders is 28,237 [2]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary has received a notification for the approval of the chemical raw material drug, Mirabegron, which is primarily used for treating overactive bladder (OAB) conditions such as urinary incontinence, urgency, and frequency [1] Group 1: Product Approval and Market Impact - Mirabegron is a selective β-3 adrenergic receptor agonist, and its approval indicates compliance with national technical standards for raw material drug review [1] - The approval allows for production and sales in the domestic market, enhancing the company's product line in raw materials and improving its competitiveness in the chemical raw material drug sector [1] Group 2: Market Data and Trends - Currently, there are 18 companies in China with Mirabegron approval status A on the raw material drug registration platform [1] - According to IMS data, global consumption of Mirabegron raw materials is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - Global sales of Mirabegron formulations are expected to reach $3.286 billion in 2022, $3.420 billion in 2023, and $3.536 billion in 2024 [1]

Core Viewpoint - The company has submitted a patent application for a method and application of nicotine salt compounds, which aims to address the issue of nicotine release not matching human metabolism, particularly the insufficient release in later stages [1] Company Summary - The subsidiary of the company has filed a patent application for the preparation method and application of nicotine salt compounds, which is currently under review [1]

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Mirabegron [1] Group 1 - The approval notification number is 2025YS00837 [1] - The drug approved is a chemical raw material named Mirabegron [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] - Mirabegron is indicated for the treatment of overactive bladder (OAB), addressing conditions like urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) has received approval from the National Medical Products Administration for its chemical raw material drug, Mirabegron, which is a selective β-3 adrenergic receptor agonist used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Group 1 - The company’s wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., is responsible for the approval of Mirabegron [1] - Mirabegron is specifically indicated for the treatment of overactive bladder (OAB) [1] - The approval marks a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice for the marketing application of the chemical raw material drug Mirabegron from the National Medical Products Administration [1] Group 1 - The chemical raw material drug approved is named Mirabegron, which is a selective β-3 adrenergic receptor agonist [1] - Mirabegron is primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used for treating overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical announced on September 23 that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] Industry Summary - Mirabegron is classified as a selective β-3 adrenergic receptor agonist and is indicated for the treatment of overactive bladder (OAB), which includes symptoms like urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of Mirabegron active pharmaceutical ingredient, enhancing the company's product line and market competitiveness [1] Summary by Relevant Sections - **Approval Announcement** - The company announced that it has received the approval notice for the marketing application of Mirabegron active pharmaceutical ingredient [1] - **Product Information** - Mirabegron is a selective β-3 adrenergic receptor agonist primarily used for the treatment of overactive bladder [1] - **Market Data** - According to IMS data, the global consumption of Mirabegron active pharmaceutical ingredient is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - **Strategic Implications** - The approval will enrich the company's active pharmaceutical ingredient product line and enhance its market competitiveness [1]